Allied Health & Imaging · Independent exam preparation
Scientist in Hematology – H(ASCP): Free Preparation Guide Study Guide
Interpret blood counts, distinguish anemia and neoplasia, resolve coagulation patterns, and troubleshoot laboratory results for Scientist in Hematology H(ASCP).
By CertMedbry · Updated 15 October 2026
Practise connecting cell physiology with morphology, calculating defensible laboratory results, distinguishing anemia mechanisms, and resolving coagulation abnormalities. This guide develops 60 selected concepts across all five H examination domains, followed by original learning questions and flashcards. The official ASCP BOC content guideline defines the full examination scope; these selected lessons do not exhaust it. Use the issuer reading list to extend study into additional morphology, disorders, methods, and instrumentation.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which credential and jurisdiction does this guide follow?
It follows Scientist in Hematology – H(ASCP), using the U.S. regulatory context identified in the H outline. The issuer reading list uses Scientist, while the published content guideline retains Technologist. These names refer to the same H credential in this listing, rather than two different examinations.
ASCP H/SH Suggested Reading for Examination Preparation · Technologist in Hematology / Specialist in Hematology Examination Content Guideline
How many questions are on the examination, and how long is it?
The examination has 100 single-best-answer questions and a time allowance of 150 minutes.
Technologist in Hematology / Specialist in Hematology Examination Content Guideline
How is the examination delivered, and what question style does it use?
The examination uses computer adaptive testing, or CAT, with single-best-answer questions. The 20 questions here are fixed four-option learning drills; they do not reproduce CAT or predict an examination result. Consult ASCP BOC instructions for current appointment and testing arrangements.
Technologist in Hematology / Specialist in Hematology Examination Content Guideline
Which blueprint version applies?
The content guideline was revised September 25, 2025. The issuer reading list was reviewed April 2026. The guideline prints no separate effective date.
Technologist in Hematology / Specialist in Hematology Examination Content Guideline · ASCP H/SH Suggested Reading for Examination Preparation
How are the domains weighted?
The official ranges are Hematology Physiology 10–15%, Hematology Disease States 20–25%, Hematology Laboratory Testing 20–25%, Hemostasis 20–25%, and Laboratory Operations 15–20%. In that order, this guide allocates its 60 concepts as 8, 14, 14, 13, and 11; its 20 questions as 3, 5, 5, 4, and 3; and its 20 flashcards as 3, 4, 5, 5, and 3. Each allocation falls within the published domain ranges.
Technologist in Hematology / Specialist in Hematology Examination Content Guideline
How do H(ASCPi) and SH differ from the selected pathway?
The shared issuer documents also identify the international H(ASCPi) credential and Specialist in Hematology – SH. This guide selects H(ASCP), rather than combining eligibility or regulatory requirements across pathways. Laboratory administration marked SH ONLY is excluded. The shared outline does not establish that the credentials have interchangeable eligibility, recognition, or jurisdictional requirements.
Technologist in Hematology / Specialist in Hematology Examination Content Guideline · ASCP H/SH Suggested Reading for Examination Preparation
How should I use the reading list and confirm other examination logistics?
The issuer describes its reading list as partial preparation guidance, not an exclusive list of examinable content. The official outline remains the full scope reference. Consult current ASCP BOC candidate information for fees, scoring policies, and scheduling rules.
ASCP H/SH Suggested Reading for Examination Preparation · Technologist in Hematology / Specialist in Hematology Examination Content Guideline
This guide follows the U.S. Scientist in Hematology – H(ASCP) credential. Technologist in Hematology is the older designation retained in the published guideline and workbook listing. Specialist in Hematology – SH and the international H(ASCPi) pathway are separate credentials. The learning materials are independently authored and are not official ASCP examination items.
Outline used: H examination content guideline revised September 25, 2025; issuer reading list reviewed April 2026; checked October 9, 2026. The workbook's Technologist in Hematology designation maps to the current Scientist in Hematology – H(ASCP) credential. The published guideline retains the older name. No separate effective date or newer announced outline was found.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Hematology Physiology10–15%
1.How do hematopoietic stem cells generate different blood cell lineages?
Hematopoietic stem cells in marrow generate progenitors that progressively commit to specific blood cell lineages. Erythrocytes transport respiratory gases, leukocytes provide immune defense, and platelets support hemostasis. A shared origin does not make their mature functions interchangeable. When interpreting cytopenias, ask whether one lineage is affected or several decline together: this distinction helps organize investigation of a lineage-specific problem versus a broader production disturbance, without establishing a diagnosis by itself.
Apply it
A patient has anemia, leukopenia, and thrombocytopenia rather than isolated anemia. Organize the findings as a multilineage disturbance and examine marrow production, specimen integrity, and clinical context before attributing everything to an erythrocyte-specific disorder.
Common pitfall: Do not assume that a low count in every lineage proves marrow failure. Dilution, peripheral processes, and specimen problems can also produce combined abnormalities.
2.Why does kidney dysfunction reduce erythrocyte production?
The kidneys produce erythropoietin, a hormone that stimulates marrow erythrocyte production. Damaged kidneys may produce insufficient erythropoietin, creating an inadequate production response to anemia. Chronic kidney disease can also shorten erythrocyte survival and coexist with inflammation, blood loss, or iron and vitamin deficiencies. The useful distinction is therefore reduced marrow stimulation within a potentially multifactorial anemia, rather than an assumption that every low hemoglobin in kidney disease has one cause.
Apply it
A patient with advanced kidney disease has normocytic anemia and little reticulocyte response. Reduced erythropoietin stimulation is plausible, but review iron availability, vitamin status, and blood loss before describing the anemia as exclusively renal.
Common pitfall: A normal cell size does not exclude iron or vitamin problems, especially when several processes coexist. Kidney disease is context, not a complete etiologic explanation.
3.How does erythrocyte lifespan affect the balance between production and destruction?
Normal circulating erythrocytes survive approximately 120 days, so marrow production continually replaces aging cells. Anemia develops when production cannot match loss or destruction, even if marrow activity increases. Reticulocytosis can support compensation for shortened survival, while an inadequate reticulocyte response suggests limited production or an additional constraint. Hemolysis indicators help distinguish destruction from blood loss because both can stimulate replacement, but blood loss does not itself create the same biochemical destruction pattern.
Apply it
An anemic patient has increased reticulocytes, elevated indirect bilirubin, and reduced haptoglobin. Connect the findings to shortened erythrocyte survival with compensatory production, rather than interpreting the reticulocyte increase as evidence that anemia is absent.
Common pitfall: Reticulocytosis does not identify the cause of erythrocyte loss. Hemorrhage, hemolysis, and recovery after treatment can all increase circulating reticulocytes.
American Society of Hematology: Blood Basics · ARUP Consult: Hemolytic Anemias
4.Why is hemoglobin more informative than erythrocyte count alone for oxygen transport?
Hemoglobin within erythrocytes carries oxygen from the lungs to tissues. Erythrocyte number alone does not describe the amount of hemoglobin carried because cells differ in volume and hemoglobin content. A relatively preserved or increased erythrocyte count can coexist with low hemoglobin when many cells are small. Interpret count, hemoglobin, hematocrit, and indices together; the distinction between cell number and hemoglobin mass prevents misclassification of a microcytic anemia as adequate oxygen-carrying capacity.
Apply it
A CBC shows hemoglobin 10.5 g/dL with an erythrocyte count of 5.8 × 10^12/L and marked microcytosis. Recognize anemia despite the relatively high cell count, then investigate the cause of reduced hemoglobin per cell.
Common pitfall: Do not use erythrocyte count as a substitute for hemoglobin. Numerous small cells can produce a reassuring count while total hemoglobin remains reduced.
American Society of Hematology: Blood Basics · ARUP Consult: Thalassemias
5.Which leukocyte functions help organize an abnormal differential?
Leukocytes have different immune functions, making a differential more informative than a total count alone. Neutrophils participate in rapid defense against infection, while lymphocytes include cells responsible for targeted immune responses. Functional categories help organize findings but do not establish why a population increased. Combine the absolute number of each cell type with morphology and clinical context: a high percentage may reflect loss of another population rather than a true increase in the cells highlighted.
Apply it
A differential reports 60% lymphocytes in a patient whose total WBC count is only 2.0 × 10^9/L. Calculate the absolute lymphocyte count before calling the finding lymphocytosis or interpreting the percentage as increased lymphocyte production.
Common pitfall: A percentage describes composition, not population size. Relative lymphocyte predominance can occur because neutrophils decreased, even when the absolute lymphocyte count is unremarkable.
American Society of Hematology: Blood Basics · CDC NHANES 2011–2012: Complete Blood Count Using HMX
6.How do megakaryocytes produce circulating platelets?
Platelets form from the cytoplasm of marrow megakaryocytes rather than by maturation of small nucleated blood cells. Their origin explains why circulating platelets are cytoplasmic fragments and why marrow megakaryocytes belong in an investigation of platelet production. Platelet number and platelet function remain separate questions: adequate production can yield a normal count despite defective adhesion or aggregation. A low count also requires consideration of destruction, consumption, and measurement artifacts before impaired production is assigned.
Apply it
A learner identifies a large marrow cell shedding cytoplasmic material and connects it to platelet formation. In a bleeding patient, use that production relationship while separately assessing whether the circulating platelet count and function are adequate.
Common pitfall: Do not describe platelets as small mature megakaryocytes. They are fragments of megakaryocyte cytoplasm, and their numerical adequacy does not guarantee normal hemostatic function.
ASH Image Bank: Platelet Forming Megakaryocyte · ARUP Consult: Functional Platelet Disorders
7.How does a reticulocyte response reveal marrow compensation?
Reticulocytes are recently released erythrocytes, so their abundance provides information about ongoing erythropoiesis. In anemia, an increased response can indicate compensation for peripheral loss or destruction; a weak response suggests inadequate production, although combined disorders can blunt compensation. A percentage alone is vulnerable to the reduced erythrocyte denominator. Interpret an absolute count, and when appropriate an anemia-adjusted measure, alongside hemoglobin and hemolysis indicators rather than treating any elevated percentage as sufficient marrow compensation.
Apply it
Two anemic patients both have 3% reticulocytes, but one has a much lower erythrocyte count. Calculate their absolute reticulocyte counts to compare circulating reticulocyte numbers before assuming that their marrow responses are equivalent.
Common pitfall: A percentage above the usual reference interval can still represent inadequate compensation in severe anemia. The denominator and degree of anemia change its meaning.
ARUP Consult: Hemolytic Anemias · CDC NHANES 2011–2012: Complete Blood Count Using HMX
8.How do plasma and formed elements contribute different blood functions?
Blood contains a liquid plasma compartment and formed elements with specialized functions. Plasma transports dissolved substances and proteins, while erythrocytes, leukocytes, and platelets contribute oxygen transport, defense, and hemostasis. This separation matters when interpreting tests: a cellular measurement and a plasma protein assay answer different biological questions. Reduced plasma volume can raise hemoglobin or hematocrit without increasing erythrocyte mass, producing relative erythrocytosis. Absolute erythrocytosis involves increased erythrocyte mass; concentration alone does not establish it or identify a clonal cause.
Apply it
A patient has elevated hematocrit during substantial fluid loss, with a lower result after rehydration. Consider relative erythrocytosis from reduced plasma volume before concluding that marrow erythrocyte production increased. Persistent unexplained elevation requires assessment of volume status, oxygen-related context, and other supporting findings.
Common pitfall: Counts are reported per unit volume. A concentration increase can reflect less plasma rather than more total cells, so volume context matters.
American Society of Hematology: Blood Basics · Technologist in Hematology / Specialist in Hematology Examination Content Guideline
Hematology Disease States20–25%
9.Which iron-study pattern most strongly supports iron deficiency?
Iron deficiency limits hemoglobin synthesis and commonly produces microcytic, hypochromic erythrocytes. Low ferritin supports depleted iron stores, while reduced serum iron and transferrin saturation with increased iron-binding capacity reinforce the pattern. Ferritin also responds to inflammation, so a non-low result does not always exclude deficiency in that setting. Interpret the panel together rather than relying on serum iron alone, which can be reduced in both iron deficiency and anemia of inflammation.
Apply it
An anemic patient has MCV 71 fL, low ferritin, low transferrin saturation, and increased total iron-binding capacity. Identify depleted iron stores as the coherent mechanism and distinguish the pattern from inflammation-associated iron restriction.
Common pitfall: Low serum iron alone cannot separate deficiency from inflammation. A normal or elevated ferritin can also obscure concurrent deficiency when an inflammatory response is present.
ARUP Consult: Iron Deficiency Anemia · ARUP: Iron Deficiency Anemia and Anemia of Chronic Disease/Inflammation Testing Algorithm
10.How does anemia of inflammation restrict iron delivery despite retained stores?
Inflammation-associated hepcidin elevation restricts iron movement into plasma. Hepcidin binds ferroportin, the cellular iron exporter, and promotes its internalization and destruction. This reduces transfer of absorbed intestinal iron into blood and release of recycled iron from macrophages. Iron becomes sequestered within cells, leaving less transferrin-bound iron available for erythropoiesis despite retained stores. Serum iron and transferrin saturation can therefore be low, while iron-binding capacity is often low or normal and ferritin normal or increased. Concurrent absolute iron deficiency can occur; the inflammatory pattern does not exclude depleted stores in the same patient.
Apply it
A patient with chronic inflammation has low serum iron, low iron-binding capacity, and elevated ferritin. Connect the pattern to hepcidin-mediated ferroportin removal and restricted iron export, while assessing whether concurrent absolute deficiency contributes to the anemia.
Common pitfall: Elevated ferritin does not establish adequate iron delivery to erythroid cells. Inflammation can raise ferritin and mask concurrent deficiency, so storage and availability must be assessed separately.
Story of Discovery: Erythroferrone–new regulator of iron balance - NIDDK · ARUP: Iron Deficiency Anemia and Anemia of Chronic Disease/Inflammation Testing Algorithm
11.How do morphology and metabolites distinguish vitamin B12 from folate deficiency?
Vitamin B12 and folate deficiencies impair DNA synthesis and can produce megaloblastic changes, including macro-ovalocytes and hypersegmented neutrophils. Morphology supports the shared process but does not reliably distinguish the deficient vitamin. Methylmalonic acid is useful because it increases with vitamin B12 deficiency rather than isolated folate deficiency; homocysteine can increase in either. Renal dysfunction can also increase methylmalonic acid, so biochemical interpretation must include renal context rather than treating a single abnormal metabolite as definitive.
Apply it
A patient has macro-ovalocytes, hypersegmented neutrophils, and borderline vitamin B12. Elevated methylmalonic acid with preserved renal function strengthens the case for B12 deficiency and helps distinguish it from isolated folate deficiency.
Common pitfall: Macrocytosis is not synonymous with megaloblastic anemia, and methylmalonic acid is not specific without context. Renal impairment can complicate its interpretation.
12.Which findings favor beta-thalassemia trait over iron deficiency?
Beta-thalassemia trait reduces beta-globin synthesis and often produces pronounced microcytosis with a relatively preserved or increased erythrocyte count. Increased HbA2 supports the diagnosis when interpreted with hemoglobin analysis and iron status. Iron deficiency more often shows depleted ferritin and a different iron-study pattern. Neither microcytosis nor erythrocyte count alone establishes thalassemia; coexisting deficiency and method-dependent hemoglobin findings can complicate interpretation, making integrated assessment more reliable than a screening ratio by itself.
Apply it
An adult has MCV 64 fL, only mild anemia, a relatively high erythrocyte count, normal iron stores, and increased HbA2. Connect the disproportionate microcytosis and hemoglobin fraction pattern to beta-thalassemia trait.
Common pitfall: Do not diagnose thalassemia from microcytosis alone. Iron deficiency can coexist and may affect HbA2 interpretation, so iron status remains relevant.
13.How does an HBB variant cause sickling, and how is the pattern investigated?
Sickle hemoglobin arises from an HBB variant that changes beta-globin and permits deoxygenated hemoglobin to polymerize. The resulting erythrocyte deformation contributes to hemolysis and impaired microvascular passage. Hemoglobin fractionation helps characterize the pattern, but detection of HbS alone does not distinguish every genotype. Interpret the presence of HbA, HbF, and other fractions with transfusion history and complementary testing; molecular analysis can resolve patterns that protein-based methods cannot uniquely classify.
Apply it
Hemoglobin analysis detects HbS in a recently transfused patient. Review the transfusion history before interpreting the accompanying HbA as proof of trait, and consider molecular clarification if the patient's underlying genotype remains uncertain.
Common pitfall: HbS detection identifies a hemoglobin variant, not automatically a specific disease genotype. Recent transfusion can alter fractions and create misleading apparent combinations.
14.How can spherocytes arise from either immune or inherited membrane disease?
Spherocytes reflect reduced erythrocyte surface area relative to volume and may occur in hereditary spherocytosis or immune-mediated hemolysis. The smear therefore identifies a shape abnormality rather than a unique cause. A direct antiglobulin test assesses cell-bound immunoglobulin or complement and supports an immune mechanism when appropriately interpreted. Hereditary spherocytosis assessment instead combines family and clinical findings with membrane-focused testing such as eosin-5-maleimide binding. Hemolysis evidence establishes increased destruction but does not settle the mechanism.
Apply it
A patient with lifelong anemia, family history, spherocytes, and a negative DAT undergoes membrane-focused testing. Another patient with new hemolysis and a positive DAT requires an immune interpretation rather than the same inherited diagnosis.
Common pitfall: Spherocytes are not diagnostic of hereditary spherocytosis. A negative DAT also requires context because test sensitivity and uncommon immune mechanisms can complicate interpretation.
15.Why can G6PD testing appear normal during an acute hemolytic episode?
G6PD supports protection against oxidative injury in erythrocytes. During an acute episode, the most deficient older cells may be preferentially destroyed, leaving younger cells and reticulocytes with higher enzyme activity. An activity assay can therefore appear reassuring despite underlying deficiency. Recent transfusion can also mask the patient's enzyme pattern. When clinical suspicion persists, interpret the timing and cell population and arrange reassessment after recovery rather than treating one acute-phase result as exclusion.
Apply it
A patient develops hemolysis after an oxidative exposure, but G6PD activity is within the laboratory interval during marked reticulocytosis. Recognize the surviving-cell bias and plan reassessment after recovery rather than dismissing the suspected deficiency.
Common pitfall: A normal acute-phase enzyme result does not reliably exclude G6PD deficiency. Reticulocytosis and donor erythrocytes can both produce falsely reassuring activity.
16.How does loss of GPI-linked proteins identify a PNH clone?
Paroxysmal nocturnal hemoglobinuria involves a hematopoietic clone deficient in glycosylphosphatidylinositol-linked surface proteins. Loss of complement-regulating proteins contributes to hemolysis, while the disorder can also involve thrombosis and cytopenias. Flow cytometry detects the deficient populations using appropriate GPI-associated markers and reagents such as FLAER on suitable leukocyte populations. Evaluate more than erythrocytes alone: hemolysis and transfusion can alter the circulating erythrocyte population and distort the apparent size of the clone.
Apply it
A patient with unexplained intravascular hemolysis and cytopenias has a GPI-deficient granulocyte population on flow cytometry. Use lineage-appropriate marker combinations to characterize the clone rather than relying solely on the erythrocyte result after transfusion.
Common pitfall: FLAER is not an interchangeable reagent for every cell population. Erythrocyte-only assessment may underestimate a clone after hemolysis or transfusion.
17.Which findings distinguish acute myeloid or lymphoid leukemia from a myelodysplastic pattern?
Acute leukemias involve expansion of immature cells that impairs normal hematopoiesis, producing cytopenias even when total WBC is increased. Myeloperoxidase supports myeloid differentiation; strong cytoplasmic or surface CD3 supports T lineage, while B lineage requires a coherent CD19-associated marker pattern. Morphology alone cannot reliably assign lineage, and absent myeloperoxidase does not establish ALL. Nonspecific esterase contributes evidence of monocytic differentiation within a broader panel. See the [NCI acute-leukemia discussion](https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq). Myelodysplastic neoplasia instead commonly presents with cytopenias and abnormal maturation, including hypogranular or pseudo-Pelger-Huët granulocytes and micromegakaryocytes. A cellular marrow can coexist with ineffective blood-cell production. Marrow morphology, blast enumeration, cytogenetics, and molecular findings distinguish patterns; genetics and the classification framework affect the boundary with AML. See the [NCI myelodysplasia discussion](https://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq).
Apply it
Compare a blast-rich marrow with a coherent myeloid or lymphoid phenotype against persistent cytopenias with dysplastic granulocytes and megakaryocytes. Use lineage studies for the first and integrated dysplasia, blast, and genetic assessment for the second; assess vitamin deficiency as a potential explanation for megaloblastic changes.
Common pitfall: A high WBC count is unnecessary for acute leukemia. Neither a single aberrant antigen nor one dysplastic cell establishes classification, and a blast percentage must be interpreted with disease-defining genetics.
Technologist in Hematology / Specialist in Hematology Examination Content Guideline · ARUP Consult: Megaloblastic Anemia
18.How should reactive leukocyte changes be distinguished from possible neoplasia?
An increased leukocyte count can reflect an appropriate response or a neoplastic population. Start with the absolute differential, maturity pattern, morphology, persistence, and clinical context rather than the total count alone. A spectrum of maturation and an explanation such as infection support a reactive interpretation, while persistent unexplained abnormalities warrant further characterization. Morphology provides clues but cannot independently establish clonality. Flow, cytogenetic, or molecular studies answer additional questions according to the suspected cell population and disorder.
Apply it
A patient has neutrophilia during an acute infection. Compare the differential and smear with follow-up findings; persistent unexplained abnormalities after recovery would require a different assessment from a transient count that returns toward baseline.
Common pitfall: Neither a very high count nor a left shift alone proves leukemia. Conversely, an apparent reactive explanation should not erase persistent unexplained abnormalities.
Technologist in Hematology / Specialist in Hematology Examination Content Guideline · ARUP Consult: Chronic Myeloid Leukemia
19.Why is BCR::ABL1 testing decisive in the appropriate CML context?
Chronic myeloid leukemia is characterized by BCR::ABL1, a fusion associated with constitutive tyrosine kinase activity. Leukocytosis with granulocytic maturation and basophilia can raise suspicion, but these findings require genetic confirmation rather than a morphology-only diagnosis. Cytogenetics, fluorescence in situ hybridization, and molecular assays provide different views of the abnormality. Interpret the result in its hematologic setting because BCR::ABL1 can also occur in other leukemia contexts, and transcript identification matters for subsequent molecular measurement.
Apply it
An adult has persistent leukocytosis, granulocytes spanning maturation stages, and basophilia. Select BCR::ABL1 testing to evaluate suspected CML, then integrate the result with marrow, cytogenetic, and clinical findings rather than stopping at the smear.
Common pitfall: BCR::ABL1 is not a context-free label for every leukemia carrying the fusion. Morphology and lineage remain necessary to classify the disease correctly.
20.How do the iwCLL criteria distinguish CLL, monoclonal B-cell lymphocytosis, and SLL?
Under the 2018 iwCLL framework, the usual blood-based CLL diagnosis requires at least 5 × 10^9/L circulating clonal B lymphocytes sustained for at least three months, with characteristic morphology and immunophenotype. Flow cytometry confirms light-chain restriction; typical cells coexpress CD19, CD5, and CD23 with relatively weak CD20 and surface immunoglobulin. Below 5 × 10^9/L, monoclonal B-cell lymphocytosis applies when lymphadenopathy, organomegaly, disease-related cytopenias, and symptoms are absent. SLL requires tissue involvement, fewer than 5 × 10^9/L circulating B cells, and absence of cytopenias caused by clonal marrow infiltration. A cytopenia caused by a characteristic marrow infiltrate establishes CLL regardless of circulating B-cell count. These are integrated iwCLL criteria, not a count-only universal rule.
Apply it
A characteristic clonal B-cell population remains between 6.0 and 6.4 × 10^9/L over four months, meeting the iwCLL duration and count requirements. Compare a 3.0 × 10^9/L clone without other disease findings, consistent with MBL, with the same lower count plus anemia proven to result from characteristic marrow infiltration, which establishes CLL.
Common pitfall: Use the absolute clonal B-cell count rather than total lymphocytes. CD5 positivity alone is insufficient, and anemia must be attributed to the characteristic marrow infiltrate before applying the lower-count exception.
iwcll-guideline-hallek-et-al-2018.pdf · SEER Hematopoietic and Lymphoid Neoplasm Database
21.How do platelet number and platelet function create different bleeding problems?
Platelet disorders can be quantitative, qualitative, or both. A reduced count limits the available platelet population, while a functional defect can impair adhesion or aggregation despite a normal count. Begin by confirming the count and reviewing the smear for clumping or other artifacts. If mucocutaneous bleeding persists with adequate numbers, investigate platelet and von Willebrand function in context. Medication effects and other acquired influences must be considered before attributing an abnormal function result to an inherited disorder.
Apply it
A patient has recurrent mucosal bleeding with a normal platelet count. Treat the normal count as evidence about quantity, then assess the bleeding history, medications, von Willebrand studies, and appropriate platelet function testing.
Common pitfall: A normal platelet count does not exclude a platelet-related bleeding disorder. Conversely, an unexpectedly low automated count may reflect clumping rather than true thrombocytopenia.
46.How does severe ADAMTS13 deficiency discriminate TTP within thrombotic microangiopathy?
Thrombotic microangiopathy combines microangiopathic hemolysis and thrombocytopenia in an appropriate clinical setting. Severe ADAMTS13 activity deficiency, below 10%, strongly supports thrombotic thrombocytopenic purpura. ADAMTS13 normally cleaves VWF multimers; marked deficiency permits abnormal platelet-rich microvascular thrombosis. Schistocytes and thrombocytopenia raise the syndrome but do not identify its cause. Obtain an appropriate pretreatment specimen when feasible, and recognize that urgent clinical assessment should not depend on waiting for a delayed confirmatory result.
Apply it
A patient has thrombocytopenia, schistocytes, biochemical hemolysis, and ADAMTS13 activity of 4%. Interpret severe deficiency as strong support for TTP, distinguishing it from other microangiopathies that do not share this defining laboratory finding.
Common pitfall: Schistocytes alone do not diagnose TTP. Borderline ADAMTS13 reductions are not equivalent to activity below 10%, and treatment can affect subsequent laboratory interpretation.
ISTH Guidelines for the Diagnosis of Thrombotic Thrombocytopenic Purpura · ARUP Consult: Thrombotic Microangiopathies · Technologist in Hematology / Specialist in Hematology Examination Content Guideline
Hematology Laboratory Testing20–25%
22.How are MCV, MCH, and MCHC calculated from CBC measurements?
With conventional units, MCV equals hematocrit in percent multiplied by 10 divided by erythrocyte count in millions per microliter. MCH equals hemoglobin in g/dL multiplied by 10 divided by that count. MCHC equals hemoglobin multiplied by 100 divided by hematocrit in percent. The indices describe cell volume, hemoglobin per cell, and hemoglobin concentration within the cell volume. Distinguish these denominators and verify units before interpreting an apparently abnormal result.
Apply it
For hemoglobin 12 g/dL, hematocrit 36%, and erythrocytes 4.0 × 10^12/L, calculate MCV 90 fL, MCH 30 pg, and MCHC 33.3 g/dL. Check that each result describes a different property.
Common pitfall: Using fractional hematocrit in a formula written for percent creates a major error. MCH and MCHC also cannot be interchanged despite similar names.
23.Which component patterns distinguish turbidity from erythrocyte agglutination when MCHC is implausible?
MCHC equals hemoglobin divided by hematocrit, so interference in either component can produce an implausible ratio. Turbidity, such as lipemia, can falsely increase photometrically measured hemoglobin: hemoglobin, MCH, and MCHC may be high despite relatively coherent RBC and MCV measurements. Erythrocyte agglutination instead distorts cell counting and sizing, commonly producing a low RBC count and increased MCV; hematocrit derived from those measurements becomes unreliable, and calculated indices may rise. Turbid plasma supports the first pattern; erythrocyte clusters on the smear support the second. These relationships are described in the historical CDC NHANES 2011–2012 Beckman Coulter HMX method document; current correction procedures remain platform specific.
Apply it
For an implausible MCHC, compare hemoglobin with RBC, MCV, and derived hematocrit. Turbid plasma with disproportionately high hemoglobin directs attention to a validated hemoglobin-interference correction or alternate measurement. A low RBC count, increased MCV, and smear agglutinates direct attention to agglutination; a validated warming and repeat-analysis procedure may resolve temperature-dependent clustering. Confirm component agreement before reporting.
Common pitfall: Do not diagnose spherocytosis from an extreme MCHC alone or apply the same correction to both patterns. Correcting hemoglobin turbidity does not resolve distorted cell measurements, and warming does not remove a turbidity-related hemoglobin bias.
CDC NHANES 2011–2012: Complete Blood Count Using HMX · WHO Laboratory Quality Management System: Quality Control Chapters
24.How is an absolute leukocyte subtype count calculated?
An absolute subtype count equals the total WBC concentration multiplied by the subtype fraction. Convert the percentage to a decimal and retain the WBC concentration units. When a defined calculation includes neutrophils and bands, add their percentages before multiplying. Absolute counts prevent a compositional change from being mistaken for a true population increase or decrease. Check that the total WBC result is valid, including any applicable nucleated erythrocyte correction, before calculating subtype counts from it.
Apply it
A WBC count of 4.0 × 10^9/L with 30% segmented neutrophils and 5% bands yields 1.4 × 10^9/L for the combined neutrophil count. Compare that value with the relevant laboratory interval.
Common pitfall: Multiplying by 35 rather than 0.35 creates a hundredfold error. A subtype percentage alone cannot establish an absolute cytopenia or cytosis.
25.When is a nucleated erythrocyte correction needed for WBC results?
Some counting methods include nucleated erythrocytes in an apparent WBC count. When the count is uncorrected, corrected WBC equals the reported count multiplied by 100 divided by 100 plus the nucleated erythrocytes counted per 100 WBCs. The correction removes their contribution to the denominator population. Modern analyzers may already identify and correct for these cells, so determine what the reported parameter represents before applying the formula. Duplicate correction produces an incorrectly low WBC result.
Apply it
An explicitly uncorrected WBC count is 18.0 × 10^9/L, with 20 nucleated erythrocytes per 100 WBCs. Calculate 18.0 × 100/120, giving a corrected WBC count of 15.0 × 10^9/L.
Common pitfall: Do not correct an analyzer result that already excludes nucleated erythrocytes. Also distinguish cells per 100 WBCs from a percentage using a different denominator.
26.How does chamber geometry determine a manual cell count?
A manual chamber count converts observed cells into a concentration using the volume examined and any specimen dilution. Concentration equals cells counted multiplied by the dilution factor, divided by counted volume. Counted volume is the selected area multiplied by chamber depth, with compatible units. Define the squares and boundary convention before counting, and assess chamber loading and agreement between replicate areas. The formula is stable; the actual volume and dilution must come from the method used.
Apply it
A diluted blood specimen yields 80 cells in 0.4 µL of chamber volume at a dilution factor of 20. Calculate 80 × 20/0.4 = 4,000 cells/µL, then assess replicate agreement before reporting.
Common pitfall: Memorizing a multiplication factor without its geometry is unsafe. A factor valid for one counted area or dilution may be wrong for another.
Technologist in Hematology / Specialist in Hematology Examination Content Guideline
27.How should body fluid counts preserve both concentration and cellular context?
Body fluid cell counting requires a defined specimen type, a valid counting method, and a clear distinction between total nucleated cells and any separate erythrocyte count. Manual calculations use the same cells-per-volume principle as blood, but fluid-specific method performance and cell differentiation remain important. A total nucleated count does not identify the cells present. Pair concentration with an appropriate differential and morphology, and use reference or decision limits applicable to that fluid rather than blood intervals.
Apply it
An undiluted fluid sample yields 24 nucleated cells in 0.9 µL. Calculate approximately 26.7 cells/µL, then interpret the result with the fluid type and differential rather than applying the blood WBC reference interval.
Common pitfall: Do not treat every nucleated fluid cell as a leukocyte without differentiation. Blood reference intervals and blood analyzer assumptions do not automatically transfer to fluids.
Technologist in Hematology / Specialist in Hematology Examination Content Guideline
28.How do absolute and anemia-adjusted reticulocyte measurements differ?
The absolute reticulocyte count equals erythrocyte count multiplied by the reticulocyte fraction and expresses circulating reticulocyte concentration. Anemia reduces the erythrocyte denominator, potentially making a raw percentage appear disproportionately high. A corrected percentage instead multiplies the observed percentage by patient hematocrit divided by an explicitly selected reference hematocrit. A reticulocyte production index additionally applies a maturation adjustment. These measurements answer related but different questions; none independently establishes adequate compensation without considering anemia severity.
Apply it
With erythrocytes 2.5 × 10^12/L and reticulocytes 4%, the absolute count is 100 × 10^9/L. In a separate scenario specifying reticulocytes 6%, hematocrit 24%, and reference hematocrit 48%, the corrected percentage is 3%. That corrected percentage is not a production index unless a specified maturation adjustment is also applied.
Common pitfall: Convert percentages to fractions and preserve concentration units. Do not confuse corrected percentage with production index or invent a reference hematocrit or maturation factor.
CDC NHANES 2011–2012: Complete Blood Count Using HMX · ARUP Consult: Hemolytic Anemias · Technologist in Hematology / Specialist in Hematology Examination Content Guideline
29.Which cellular cues distinguish reactive mesothelial cells from macrophages in body fluids?
In serous effusions, reactive mesothelial cells can form cohesive groups with spaces or windows between adjacent cells. Abundant basophilic cytoplasm, central round nuclei, and prominent nucleoli may accompany reactive change; mild atypia alone does not establish malignancy. The [ASH pericardial-fluid example](https://imagebank.hematology.org/image/66359/reactive-mesothelial-cells-in-pericardial-effusion-1) demonstrates this pattern. Macrophages often have abundant foamy or vacuolated cytoplasm containing phagocytosed material and round or kidney-shaped nuclei; marked vacuolation can produce a signet-ring appearance. See the [ASH lavage-fluid example](https://imagebank.hematology.org/image/64968/macrophage-in-balf). Evaluate architecture, chromatin, cytoplasm, and the fluid compartment together. Persistent suspicious atypia requires cytologic assessment and appropriate ancillary studies because reactive and neoplastic appearances can overlap.
Apply it
A pericardial-fluid preparation contains cohesive large basophilic cells with central nuclei and intercellular windows, alongside separate foamy phagocytic cells. Identify the first pattern as supporting reactive mesothelial cells and the second as supporting macrophages; distinguish both from the leukocytes in the differential.
Common pitfall: Prominent nucleoli do not independently establish cancer. A signet-ring appearance can occur in macrophages, and a total nucleated count cannot resolve cellular identity.
Technologist in Hematology / Specialist in Hematology Examination Content Guideline
30.How does erythrocyte morphology narrow an anemia investigation?
Morphology describes patterns that guide testing rather than supplying a diagnosis in isolation. Microcytosis and hypochromia suggest impaired hemoglobin production; macro-ovalocytes with hypersegmented neutrophils support a megaloblastic process; spherocytes raise membrane or immune possibilities; and fragments suggest mechanical injury in an appropriate setting. Connect shapes with indices, reticulocytes, and biochemical results. A mixed population can make the average MCV appear unremarkable, so review distribution and smear findings rather than relying only on a mean.
Apply it
An anemic patient's MCV is within the laboratory interval, but the smear contains both small hypochromic cells and large oval cells. Recognize that averaging may conceal two populations and investigate the contrasting morphologic clues.
Common pitfall: A normal mean does not prove a uniform population. Morphologic patterns overlap, so avoid assigning a specific cause from a single cell shape.
ARUP Consult: Iron Deficiency Anemia · ARUP Consult: Megaloblastic Anemia · ARUP Consult: Hemolytic Anemias
31.How should an abnormal WBC scattergram be reconciled with the smear?
A scattergram separates measured cell events according to instrument signals and classification rules. An abnormal cluster or flag indicates uncertainty or an unusual population; it is not a final morphologic diagnosis. Nucleated erythrocytes and abnormal leukocytes can affect population separation and counting. Review the affected parameters, determine whether automated correction or classification occurred, and examine the smear when required by the laboratory's validated process. The goal is to reconcile event classification with actual cells before reporting.
Apply it
An analyzer flags an abnormal WBC scattergram and possible nucleated erythrocytes. Review the smear and instrument parameter definitions, then decide whether the WBC count and differential are valid or require the laboratory's established follow-up procedure.
Common pitfall: A flag is a prompt for assessment, not a named disease. Manual correction without checking the analyzer's existing handling can introduce another error.
32.What does Prussian blue staining reveal about marrow iron?
Prussian blue staining demonstrates stainable iron in marrow material and supports assessment of storage iron and erythroid iron distribution. It answers a different question from cell size or serum iron alone. Adequate material and staining performance are essential before interpreting absent staining as depleted stores. Correlate the result with peripheral indices and iron studies, and distinguish iron in storage cells from iron associated with erythroid precursors rather than reducing every positive reaction to one undifferentiated finding.
Apply it
A marrow preparation from a patient with microcytic anemia is assessed for stainable storage iron. Interpret absent staining only after confirming specimen adequacy and staining performance, then compare the finding with ferritin and other iron studies.
Common pitfall: An inadequate or poorly stained preparation can mimic absent iron. Prussian blue demonstrates stainable iron, not every aspect of iron availability or metabolism.
ASH Image Bank: Iron Deficiency Anemia—Stains · ARUP Consult: Iron Deficiency Anemia
33.How do hemolysis indicators and the DAT answer different questions?
Reticulocytosis, increased lactate dehydrogenase and indirect bilirubin, and reduced haptoglobin can support hemolysis when interpreted together. These findings assess destruction and compensation. The direct antiglobulin test instead evaluates immunoglobulin or complement associated with erythrocytes and helps investigate an immune mechanism. A positive DAT does not independently prove active hemolysis, while a negative result does not settle every possible immune process. First establish the destruction pattern, then use mechanism-directed testing to explain it.
Apply it
A patient's DAT is positive, but hemoglobin is stable and biochemical evidence of hemolysis is absent. Describe cell-associated immune material without automatically diagnosing active hemolytic anemia; correlate with the patient's clinical and laboratory pattern.
Common pitfall: Do not equate DAT positivity with hemolysis or use a single elevated LDH as proof of erythrocyte destruction. Each result answers a narrower question.
34.Why may hemoglobin fractionation require a complementary method?
Hemoglobin fractionation methods separate proteins according to method-dependent physical or chemical properties. A peak or migration position may not uniquely identify every variant because some hemoglobins overlap or behave similarly in one system. Complementary methods and, when needed, molecular testing improve classification. Review transfusion history and the complete fraction pattern before interpretation. Protein analysis characterizes circulating hemoglobin, whereas DNA analysis addresses the underlying variant; these approaches are related but answer different questions.
Apply it
A fractionation result shows an unusual peak that the method cannot uniquely identify. Use a complementary method or molecular analysis rather than naming a variant solely from its position, and check whether recent transfusion altered the pattern.
Common pitfall: One peak position is not universally specific across methods. Donor hemoglobin and overlapping variants can make an apparently simple fraction pattern misleading.
ARUP Consult: Hemoglobinopathies · ARUP Consult: Thalassemias
35.How do protein studies and marrow assessment distinguish plasma cell dyscrasias?
Serum protein electrophoresis quantifies an M protein; immunofixation identifies its heavy- and light-chain type. Serum free-light-chain assays help detect light-chain or low-secretion disease. Total immunoglobulin measurement also includes normal immunoglobulins, so it does not selectively quantify the clone. Classification requires monoclonal protein studies, clonal marrow plasma-cell percentage, and assessment for myeloma-defining events. Non-IgM MGUS requires serum M protein below 30 g/L, clonal marrow plasma cells below 10%, and no attributable CRAB injury or amyloidosis. Smoldering myeloma requires serum IgG or IgA M protein at least 30 g/L, urinary monoclonal protein at least 500 mg/24 hours, and/or clonal marrow plasma cells at least 10% but below 60%, with no myeloma-defining event or amyloidosis. Active myeloma requires at least 10% clonal marrow plasma cells or a biopsy-proven plasmacytoma, plus at least one myeloma-defining event. These include attributable CRAB injury: calcium above 11 mg/dL or more than 1 mg/dL above the upper reference limit; creatinine clearance below 40 mL/min or serum creatinine above 2 mg/dL; hemoglobin below 10 g/dL or more than 2 g/dL below the lower reference limit; or osteolytic bone disease. Active disease can also be established before CRAB injury by any one biomarker: clonal marrow plasma cells at least 60%; involved/uninvolved free-light-chain ratio at least 100 with involved concentration at least 100 mg/L; or more than one MRI focal lesion, each at least 5 mm.
Apply it
Consider three classification examples with serum IgG M protein of 20 g/L, no attributable CRAB injury, no amyloidosis, and negative imaging. With 7% clonal marrow plasma cells and no qualifying free-light-chain biomarker, the classification is non-IgM MGUS. With 18% clonal marrow plasma cells and no qualifying biomarker, it is smoldering myeloma despite the M protein remaining below 30 g/L. With 18% clonal marrow plasma cells, involved kappa free light chains of 240 mg/L and uninvolved lambda of 2 mg/L, the ratio is 120. Both light-chain thresholds are met, establishing active myeloma without CRAB injury.
Common pitfall: An M protein alone does not diagnose active myeloma, and a small or absent electrophoresis peak does not exclude light-chain disease. Anemia from iron deficiency or renal dysfunction from another cause does not automatically satisfy attributable CRAB injury. Use the involved/uninvolved ratio; for a lambda clone, this is lambda divided by kappa. If marrow contains fewer than 10% clonal plasma cells and bone lesions are the defining feature, more than one bone lesion is required to distinguish myeloma from solitary plasmacytoma with minimal marrow involvement.
Technologist in Hematology / Specialist in Hematology Examination Content Guideline · Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®) - NCI · IMWG Criteria for the Diagnosis of MM | Inl Myeloma Fn
Hemostasis20–25%
36.How do primary and secondary hemostasis create different bleeding clues?
Primary hemostasis depends on platelet interaction with the vessel injury and von Willebrand factor, while secondary hemostasis generates fibrin through coagulation reactions. Mucocutaneous bleeding often directs attention toward platelet or VWF abnormalities; deep tissue or joint bleeding raises coagulation-factor possibilities. These are organizing clues rather than absolute rules. Platelet count, VWF assays, and coagulation studies interrogate different components, so select and interpret them according to the bleeding pattern rather than expecting one screening result to assess all hemostasis.
Apply it
A patient has recurrent epistaxis and easy bruising with a normal platelet count. Prioritize investigation of VWF and platelet function in the appropriate clinical assessment rather than assuming a normal count establishes intact primary hemostasis.
Common pitfall: Bleeding patterns overlap. Normal platelet numbers and normal screening clotting times cannot exclude every clinically important defect of primary or secondary hemostasis.
ARUP Consult: Von Willebrand Disease · ARUP Consult: Hemophilia—Factor VIII or IX Deficiency
37.Which factors and bleeding associations discriminate PT and aPTT patterns?
Isolated PT prolongation directs attention to factor VII deficiency or inhibition, although drugs and acquired disorders can produce the same pattern. Isolated aPTT prolongation can reflect factors VIII, IX, or XI, whose deficiencies are associated with bleeding, or contact factors XII, prekallikrein, and high-molecular-weight kininogen, whose deficiencies prolong the assay without the corresponding bleeding phenotype. Common-pathway abnormalities involving factors II, V, X, or fibrinogen can prolong both PT and aPTT; multiple deficiencies and anticoagulants can also do so. Assay sensitivity influences the observed pattern. Verify collection and drug exposure before assigning a factor disorder.
Apply it
Compare an isolated prolonged aPTT in a patient with joint bleeding against the same screening pattern in an asymptomatic patient. The first favors investigation of VIII or IX deficiency; the second includes contact-factor deficiency and lupus anticoagulant. Isolated PT suggests VII assessment, while prolongation of both directs attention to common-pathway or broader causes.
Common pitfall: The duration of aPTT prolongation does not directly measure bleeding severity. Normal PT and aPTT can still occur in factor XIII deficiency, and specimen or drug interference must be excluded.
ARUP Consult: Prolonged Clotting Time Evaluation · ARUP Consult: Hemophilia—Factor VIII or IX Deficiency · ARUP Consult: Uncommon Factor Deficiencies
38.How do immediate and incubated mixing studies distinguish deficiency from inhibition?
A mixing study combines patient plasma with normal plasma to determine whether supplied factors correct a prolonged clotting time. Correction supports deficiency; persistent prolongation suggests an inhibitor or drug effect. Some factor VIII inhibitors act over time: an immediate mixture can correct, while an incubated mixture loses correction as supplied factor is inhibited. Use validated correction criteria and appropriate incubation controls. A weak inhibitor can be diluted by mixing, so correction does not absolutely exclude inhibition. Factor assays and inhibitor testing characterize the suspected mechanism.
Apply it
A prolonged aPTT corrects immediately but fails the laboratory's correction criterion after incubation in a patient with new bleeding. After excluding anticoagulant interference, investigate a time-dependent inhibitor with factor activity and appropriate inhibitor testing rather than interpreting the immediate result as uncomplicated deficiency.
Common pitfall: Correction does not identify the deficient factor. Noncorrection does not independently distinguish a specific factor inhibitor, lupus anticoagulant, or a drug; incubation adds information but does not itself confirm antibody identity.
ARUP Consult: Hemophilia—Factor VIII or IX Deficiency · ARUP Consult: Prolonged Clotting Time Evaluation
39.How do inherited thrombophilia mechanisms determine the appropriate laboratory assays?
Factor V Leiden disrupts an activated-protein-C cleavage site, allowing factor V activity to persist; the prothrombin G20210A variant increases prothrombin levels. Targeted DNA assays identify these variants. Antithrombin, protein C, and protein S deficiencies instead reduce natural anticoagulant capacity and are generally investigated with activity or antigen measurements. A low protein result can be acquired: warfarin lowers protein C and S, pregnancy lowers free protein S, and recent thrombosis or illness can affect results. The [BSH thrombophilia guideline](https://onlinelibrary.wiley.com/doi/10.1111/bjh.18239) explains these distinctions. DOAC interference is method dependent; clot-based protein C or S activity can be overestimated, masking deficiency. DNA detection and functional phenotype therefore answer different questions.
Apply it
A patient taking warfarin after recent thrombosis has low protein S. The result does not establish inherited deficiency. Interpret treatment, timing, and assay choice before reassessment; a targeted F5 DNA result addresses a separate mechanism.
Common pitfall: One abnormal activity or antigen result does not prove inheritance. A normal result during drug interference may also be falsely reassuring; testing should answer a defined clinical question.
Impact%20of%20Anticoagulants%20on%20Coagulation%20Testing_web.pdf · Technologist in Hematology / Specialist in Hematology Examination Content Guideline
40.How do factor VIII and IX assays distinguish hemophilia A from B?
Hemophilia A involves factor VIII deficiency and hemophilia B factor IX deficiency. Both can produce a similar bleeding pattern and prolonged aPTT, so the screening result cannot distinguish them. Specific factor activity assays provide the discriminating evidence. Factor VIII also depends on VWF for stabilization, making low VIII activity a finding that may require VWF assessment. Assay interference and inhibitor effects must be considered when the activity result conflicts with history, mixing behavior, or other studies.
Apply it
A patient with recurrent joint bleeding has prolonged aPTT and a deficiency-type mixing result. Measure factor VIII and IX activity to distinguish the hemophilias, and investigate VWF if low factor VIII requires a broader explanation.
Common pitfall: A prolonged aPTT does not distinguish hemophilia A from B. Low factor VIII activity is also not automatically isolated hemophilia A.
ARUP Consult: Hemophilia—Factor VIII or IX Deficiency · ARUP Consult: Von Willebrand Disease
41.Which initial assays assess von Willebrand disease?
The initial VWD laboratory panel includes VWF antigen, platelet-dependent VWF activity, and factor VIII activity. Antigen estimates protein quantity, activity assesses relevant function, and factor VIII reflects an important consequence of VWF's carrier role. Normal PT or aPTT does not reliably exclude VWD. Results require clinical bleeding context and attention to VWF variability, because stress and other physiologic influences can change levels. Testing during a baseline state helps avoid interpreting a transient increase as reassurance.
Apply it
A patient with a convincing mucosal bleeding history has normal PT and aPTT. Obtain the VWF antigen, platelet-dependent activity, and factor VIII panel rather than ending the investigation because screening clotting times are normal.
Common pitfall: Screening clotting tests do not directly assess all VWF functions. A normal result during physiologic stress may also fail to represent the patient's baseline.
ASH ISTH NHF WFH 2021 Guidelines on the Diagnosis of von Willebrand Disease · ARUP Consult: Von Willebrand Disease
42.How does disproportionate loss of VWF activity suggest a qualitative defect?
Comparing platelet-dependent VWF activity with VWF antigen helps separate reduced amount from disproportionate functional loss. Similar reductions suggest a quantitative pattern, while substantially lower activity relative to antigen raises a qualitative type 2 pattern. The 2021 diagnostic guideline supports an activity-to-antigen ratio below 0.7 when evaluating suspected type 2A, 2B, or 2M disease after an abnormal initial screen. The ratio does not assign a complete subtype; additional assays and clinical interpretation remain necessary.
Apply it
VWF activity is 20 IU/dL and antigen 50 IU/dL, giving a ratio of 0.40. Recognize disproportionate functional impairment and pursue appropriate subtype assessment rather than describing the result as a purely proportional quantitative reduction.
Common pitfall: The activity-to-antigen ratio is not a universal subtype diagnosis. Very low measurements, assay performance, and other VWD mechanisms require careful interpretation.
ASH ISTH NHF WFH 2021 Guidelines on the Diagnosis of von Willebrand Disease
43.Which platelet aggregation pattern supports Glanzmann thrombasthenia?
Glanzmann thrombasthenia involves deficient or dysfunctional platelet integrin αIIbβ3, also called GPIIb/IIIa, impairing fibrinogen-mediated aggregation. Aggregation is markedly impaired with multiple physiologic agonists, while ristocetin-associated agglutination is generally preserved because it assesses a different interaction involving VWF and GPIb. Platelet count is usually not the central defect. Interpret aggregation with receptor studies and clinical context, accounting for medication and preanalytic effects before assigning an inherited functional disorder from an abnormal trace.
Apply it
A bleeding patient with an adequate platelet count has absent aggregation to several agonists but preserved ristocetin response. Investigate αIIbβ3 function or expression as a coherent explanation, while excluding acquired influences on the test.
Common pitfall: Ristocetin response is not the same as ordinary aggregation. Confusing its VWF–GPIb interaction with αIIbβ3 function can reverse the interpretation of the pattern.
44.Why can factor XIII deficiency cause bleeding with normal PT and aPTT?
Factor XIII stabilizes fibrin after its initial formation by cross-linking the clot. PT and aPTT terminate at an earlier clot-formation endpoint, so they can remain normal despite impaired subsequent stabilization. Unexplained delayed bleeding with normal screening times should therefore prompt consideration of disorders beyond the pathways captured by those screens. A factor XIII activity assay directly investigates the relevant deficiency. Normal screening results narrow the assessment but cannot certify that every stage of clot formation and maintenance is intact.
Apply it
A patient has delayed bleeding after procedures, normal platelet count, and normal PT and aPTT. Select factor XIII activity when the history suggests impaired clot stability rather than repeating the same normal screening tests indefinitely.
Common pitfall: Normal PT and aPTT exclude neither factor XIII deficiency nor every other bleeding disorder. Their endpoint measures initial clot formation, not complete clot stability.
45.How does DIC create a consumptive laboratory pattern?
Disseminated intravascular coagulation involves systemic coagulation activation with consumption of platelets and coagulation components and increased fibrin breakdown. A compatible pattern includes thrombocytopenia, increased D-dimer, prolonged clotting times, and falling fibrinogen, but abnormalities vary with stage and clinical context. Fibrinogen can initially remain normal or increased because it also responds to inflammation. Interpret serial results with an appropriate underlying illness rather than requiring every classic abnormality to be present simultaneously.
Apply it
A septic patient develops a falling platelet count, increasing D-dimer, prolonged PT, and declining fibrinogen over serial samples. Recognize a coherent consumptive trend even if the earliest fibrinogen result was within the laboratory interval.
Common pitfall: A normal initial fibrinogen does not exclude evolving DIC. D-dimer elevation alone is also insufficient because fibrin turnover increases in many conditions.
47.Why can lupus anticoagulant prolong a clotting assay while signaling thrombosis risk?
Lupus anticoagulant interferes with phospholipid-dependent clotting assays, producing an in vitro anticoagulant effect that does not translate into protection from thrombosis. Assessment uses sensitive screening assays, mixing behavior, and demonstration of phospholipid dependence, with attention to anticoagulant interference. The laboratory finding is distinct from a complete antiphospholipid syndrome diagnosis, which requires additional clinical and laboratory criteria. A prolonged aPTT therefore must not be interpreted automatically as a bleeding tendency or a specific factor deficiency.
Apply it
A patient investigated after thrombosis has a phospholipid-sensitive prolonged assay that fails to correct on mixing and shortens with phospholipid confirmation. Interpret the coherent lupus anticoagulant pattern after assessing medication interference and the broader clinical context.
Common pitfall: A positive lupus anticoagulant result alone does not establish antiphospholipid syndrome. Anticoagulant medications can also mimic or distort the expected assay pattern.
48.How do named anticoagulants affect assay selection and interpretation during a medication transition?
Unfractionated heparin generally prolongs aPTT and thrombin time, whereas warfarin prolongs PT/INR. Apixaban, a direct factor Xa inhibitor, may leave PT or aPTT unchanged or prolong them depending on drug concentration and reagent; normal screening times therefore do not exclude its presence. Anti-Xa quantitation must use an assay calibrated for the specific drug, such as UFH, LMWH, apixaban, or rivaroxaban. When more than one drug with anti-Xa activity is present, the reported concentration attributed to one drug can be overestimated. Anticoagulants can also create noncorrecting mixing patterns and distort factor or lupus anticoagulant assays.
Apply it
A patient transitions from apixaban to UFH while residual apixaban remains in circulation. A UFH-calibrated anti-Xa result can reflect both drugs and overestimate the concentration attributed to UFH. Review medication timing and assay susceptibility before interpreting the result as UFH alone; an apixaban-calibrated assay is also not a selective solution while another anti-Xa drug remains present.
Common pitfall: Anti-Xa assays are not interchangeable drug measurements, and drug-specific calibration does not eliminate interference from a second anti-Xa drug. Screening and specialized assay effects remain drug-, concentration-, and reagent-dependent.
Impact%20of%20Anticoagulants%20on%20Coagulation%20Testing_web.pdf · ARUP Consult: Prolonged Clotting Time Evaluation · ARUP: Lupus Anticoagulant Reflex Panel
49.What does D-dimer reveal about fibrin formation and breakdown?
D-dimer reflects breakdown of cross-linked fibrin, linking the result to prior clot formation followed by fibrinolysis. It is not simply a measure of fibrinogen concentration and does not locate a clot. Increased results can accompany DIC and other conditions with increased fibrin turnover, so an elevated value is nonspecific. Interpret it within a defined clinical or laboratory assessment and use assay-specific units and thresholds rather than transferring numerical limits between methods with different reporting conventions.
Apply it
A patient with systemic illness has an elevated D-dimer. Combine it with platelet trends, PT, fibrinogen, and clinical context when assessing DIC rather than using the D-dimer alone to identify a particular thrombotic site.
Common pitfall: D-dimer elevation does not independently diagnose DIC or a specific thrombosis. Different assays and reporting units make unsupported threshold substitution especially misleading.
Laboratory Operations15–20%
50.How do QC shifts and trends suggest different analytical problems?
A QC shift is a sustained change to a new level, whereas a trend is a progressive movement over successive measurements. Both may indicate systematic change even when some individual points remain within broad limits. Review reagent changes, calibration, maintenance, and instrument behavior against the timing of the pattern. Apply the laboratory's established acceptance rules and investigate before releasing affected results. A control chart is useful because sequence conveys information that isolated control values cannot provide.
Apply it
After a reagent change, multiple control results cluster above their former mean. Recognize a shift, assess the change and its effect on patient results, and document corrective action before accepting the analytical run.
Common pitfall: One point inside broad limits does not erase a sustained pattern. Repeating controls until a favorable result appears can conceal rather than resolve the problem.
WHO Laboratory Quality Management System: Quality Control Chapters
51.How does coefficient of variation express imprecision?
Coefficient of variation equals standard deviation divided by mean, multiplied by 100%. It expresses dispersion relative to the measurement level and supports comparison of precision when appropriate. A smaller CV indicates less relative scatter, but does not establish accuracy because results can be consistently displaced from a target. CV becomes difficult to interpret when the mean approaches zero. Evaluate precision at relevant concentrations and distinguish random variation from systematic bias rather than using one statistic to describe all analytical performance.
Apply it
A control has mean 100 and standard deviation 2 in compatible units. Calculate CV 2%. If its assigned target is 110, recognize that good repeatability can coexist with a systematic disagreement from the target.
Common pitfall: Low CV does not prove accuracy. A method can produce tightly grouped results that are consistently wrong, and near-zero means can make CV unstable.
WHO Laboratory Quality Management System: Quality Control Chapters
52.How do bias, calibration, and control material serve different purposes?
Bias describes systematic disagreement from an appropriate target or comparison. Calibration establishes the measurement relationship used by an instrument, while control material monitors whether the analytical process remains acceptably stable. These functions are related but not interchangeable. An acceptable control result does not necessarily validate every aspect of calibration or every patient matrix. When investigating systematic error, assess the assigned values, calibration history, reagent behavior, and comparison evidence instead of altering the control mean to absorb an unexplained discrepancy.
Apply it
Patient comparisons suggest a consistent positive difference despite tightly grouped controls. Investigate calibration and comparison validity rather than claiming the low control CV proves the method is unbiased or resetting the mean without explanation.
Common pitfall: Changing a control target can hide bias rather than correct it. Control stability and agreement with a valid reference are distinct performance questions.
WHO Laboratory Quality Management System: Quality Control Chapters
53.Why should QC assess more than one measurement level?
Analytical performance can differ across the reportable range, so controls at different concentrations provide information that one level cannot supply. A method may perform acceptably near the middle while showing problems at low or high values. Select control levels and acceptance rules according to the method and laboratory quality plan. When a level fails, investigate the pattern and potential patient impact rather than allowing another passing level to overrule it without a justified, established interpretation.
Apply it
An analyzer's normal-level control passes, but its low-level platelet control repeatedly fails. Investigate low-count performance and affected patient results instead of releasing every platelet result solely because the middle concentration remains acceptable.
Common pitfall: A passing control at one concentration does not validate the entire measurement range. Different levels are complementary evidence rather than votes to be averaged.
WHO Laboratory Quality Management System: Quality Control Chapters
54.How can specimen problems distort a cell count before analysis?
Cell counts depend on a representative, adequately mixed specimen suitable for the method. Clots can remove cells from the sampled suspension, and platelet clumping can create an apparent low platelet count. Instrument QC does not detect every specimen-specific defect. Inspect specimen condition and reconcile unexpected results with flags and smear findings before assigning a biological cause. Follow validated recollection or alternative-specimen procedures when required, preserving the distinction between analytical capability and the suitability of the individual sample.
Apply it
An unexpected low platelet result accompanies visible platelet clumps on the smear. Investigate an artifactual count and follow the laboratory's established alternative assessment process rather than reporting the number as confirmed patient thrombocytopenia.
Common pitfall: Passing instrument controls do not establish that each specimen is valid. Repeating the same compromised sample may reproduce the artifact instead of resolving it.
ARUP Consult: Functional Platelet Disorders · CDC NHANES 2011–2012: Complete Blood Count Using HMX
55.Which citrate collection ratio and hematocrit threshold prevent excess anticoagulant from distorting coagulation tests?
Routine coagulation collection uses nine parts blood to one part 3.2% buffered sodium citrate. Underfilling leaves too much citrate relative to blood and plasma, potentially prolonging clotting times when the assay adds calcium. Hematocrit above 55% triggers citrate adjustment in ARUP's specimen instructions: the reduced plasma volume leaves excess citrate relative to plasma even when the tube reaches its usual fill. For that collection procedure, citrate remaining in mL is C = 1.85 × 10^-3 × (100 − HCT in percent) × blood volume added in mL. The calculation specifies the citrate volume to retain, not the volume to remove.
Apply it
Using ARUP's stated example, hematocrit is 60% and 2.43 mL of blood will be added to a tube initially containing 0.27 mL citrate. Calculate C = 1.85 × 10^-3 × 40 × 2.43 = 0.17982 mL, approximately 0.18 mL to retain. Remove approximately 0.09 mL citrate under the stated collection procedure before collecting the specified blood volume.
Common pitfall: Do not confuse blood volume with total blood-plus-citrate volume, use fractional hematocrit in this percent-based formula, or remove the calculated remaining volume. Verify tube fill and the above-55% adjustment requirement before assigning unexpected prolongation to a patient factor deficiency or inhibitor.
Hemostasis-Thrombosis.pdf · ARUP Consult: Prolonged Clotting Time Evaluation · Technologist in Hematology / Specialist in Hematology Examination Content Guideline
56.How do counting principles influence hematology analyzer troubleshooting?
In electrical impedance counting, diluted cells suspended in conductive electrolyte pass through an aperture between electrodes. Each particle temporarily increases electrical resistance, producing a pulse. Pulse number reflects particle number, while pulse height reflects particle volume. The analyzer assigns events to populations using volume thresholds and distribution algorithms. An impedance platelet channel therefore recognizes platelet-sized particles rather than proving platelet identity. Erythrocyte fragments that fall within its platelet size gate generate additional accepted pulses and falsely increase the platelet count. Optical channels measure light scattered by cells passing through an illuminated flow cell; signals at defined angles provide information about size and internal structure. Their discrimination depends on the channel and its classification rules.
Apply it
For example, an impedance platelet count is 240 × 10^9/L, but the platelet histogram shows an abnormal shoulder near its upper size boundary. The smear contains numerous schistocytes, visibly reduced platelets, and no platelet clumps. This combination supports erythrocyte fragments entering the platelet gate and concealing thrombocytopenia. Verify using a validated optical or fluorescence platelet channel demonstrated to separate fragments from platelets, and inspect its population separation. If that channel yields 80 × 10^9/L with clear separation and agrees with smear findings, the discrepancy supports a falsely high impedance result. If adequate separation is unavailable, use a validated manual or reference platelet-counting procedure.
Common pitfall: Repeating the same impedance measurement may reproduce the interference precisely; reproducibility does not establish accuracy. A histogram shoulder alone cannot identify the interfering particles, so connect it with smear morphology. Platelet clumps and giant platelets can instead cause falsely low counts when excluded from the platelet gate. Optical methods can also encounter overlapping populations, so a different channel is acceptable only when its separation is adequate and its use for this interference has been validated. Do not subtract schistocyte percentages from the platelet count.
CDC NHANES 2011–2012: Complete Blood Count Using HMX · Sysmex: WBC Abnormal Scattergram with NRBC
57.How should point-of-care testing preserve laboratory quality principles?
Point-of-care location does not remove the need for controlled procedures, trained operators, suitable specimens, QC, and documented response to failures. A result must remain connected to a valid testing process regardless of where the instrument sits. Assess method limitations and comparability before treating a point-of-care measurement as interchangeable with a central laboratory result. Distinguish routine operational convenience from evidence of analytical validity, and follow the applicable quality plan when results conflict with clinical or laboratory expectations.
Apply it
A bedside hematology measurement conflicts markedly with a recent central laboratory result. Review specimen, operator, method, and QC factors, then obtain appropriate confirmation rather than choosing the more convenient number without investigating the discrepancy.
Common pitfall: Small instruments and rapid results still require quality control. Agreement at one concentration does not prove interchangeability across methods or the full measurement range.
WHO Laboratory Quality Management System: Quality Control Chapters · Technologist in Hematology / Specialist in Hematology Examination Content Guideline
58.Which protection is required when blood splashes may reach the face?
Under the U.S. OSHA Bloodborne Pathogens Standard, anticipated exposure determines appropriate protective equipment. When splashes, spray, or droplets of blood or other potentially infectious material may reach the eyes, nose, or mouth, appropriate face and eye protection is required. Gloves protect hands but do not protect facial mucous membranes. Combine suitable barriers with work practices and engineering controls, and use the laboratory's exposure-response procedure promptly after an incident rather than treating personal protective equipment as the only control.
Apply it
A technologist opens a specimen during a task with anticipated splash exposure. Use appropriate eye and face protection together with gloves and protective clothing selected for the task, while following the laboratory's established handling controls.
Common pitfall: Gloves alone cannot protect eyes or facial mucous membranes. A mask without suitable eye protection also leaves an anticipated splash route unprotected.
59.How must U.S. laboratories handle proficiency testing specimens?
CLIA proficiency testing evaluates laboratory performance through externally provided samples. Use routine patient-testing personnel, methods, and repeat practices after any preparation specified by the PT program. Do not refer PT specimens to another laboratory for testing, including referral that would ordinarily occur for patient specimens. Laboratories must not discuss or exchange PT results with other laboratories before the event reporting cutoff. This interlaboratory prohibition does not prevent required submission of results to the approved PT program. External assessment complements internal QC but does not replace daily control of the analytical process.
Apply it
A PT sample produces an unexpected result. Apply the same review and repeat practices used for patient specimens, without additional answer-seeking repeats. Do not send the sample to another laboratory or compare results with another laboratory before the cutoff; submit the laboratory's results to the PT program as required.
Common pitfall: Exceptional repeat testing can misrepresent routine performance. Distinguish prohibited interlaboratory comparison from required PT-program reporting; the latter remains an essential part of participation.
clia-brochure-proficiency-testing-and-pt-referral-october-2024.pdf · CMS: Proficiency Testing Program Requirements—General and Cytology
60.How do dilution factors and unit conversions prevent laboratory calculation errors?
A dilution factor is final volume divided by specimen volume; multiplying the diluted concentration by that factor estimates the original concentration when the method permits dilution. Serial dilution factors multiply rather than add. Track units throughout the calculation, especially cells per microliter versus cells per liter. Also check whether instrument software already applies a factor. Correct arithmetic cannot rescue an unsuitable dilution or an out-of-range measurement, so mathematical correction must remain within validated method conditions.
Apply it
A specimen undergoes a fivefold dilution followed by a twofold dilution. The total factor is ten. If the diluted result is 12 in the stated concentration units, the original is 120, provided software has not already corrected it.
Common pitfall: Adding serial factors gives the wrong dilution. Applying a factor twice can also create a plausible-looking but substantially incorrect reported concentration.
Technologist in Hematology / Specialist in Hematology Examination Content Guideline · WHO Laboratory Quality Management System: Quality Control Chapters
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Connect production, destruction, and cell function to CBC, reticulocyte, and morphology findings instead of memorizing isolated abnormalities.
- Differentiate iron deficiency, inflammation, megaloblastic disease, thalassemia, and hemolysis using coherent patterns and known interpretation limits.
- Compare reactive leukocyte changes with mature B-cell, acute-leukemia, and myelodysplastic patterns; integrate protein and marrow evidence for plasma cell disorders. Extend study through the full official outline.
- Practise corrected WBC counts, chamber geometry, absolute counts, RBC indices, dilution factors, and precision calculations with explicit units and assumptions.
- Use PT/aPTT patterns, mixing behavior, VWF panels, platelet studies, and mechanism-specific assays to distinguish hemostatic disorders and interference. Match inherited-thrombophilia mechanisms to genetic or functional assays.
- Interpret fluid cell concentration alongside compartment-specific morphology, including reactive mesothelial cells and macrophages.
- Treat QC, specimen suitability, instrumentation, point-of-care quality, U.S. OSHA safety, and CLIA proficiency testing as tested laboratory decisions.
- Use the 20-question score to identify learning needs; a fixed learning set cannot estimate performance on the computer adaptive examination.
A practical preparation plan
1. Map the complete H scope
Read the official September 25, 2025 content guideline and build a topic map for all five domains. Exclude laboratory administration marked SH ONLY. Use the April 2026 reading list to choose further resources, remembering that it is partial guidance.
2. Build mechanism-to-pattern comparisons
Create paired comparisons for deficiency versus inflammation, production versus destruction, immune versus membrane hemolysis, reactive versus clonal leukocyte changes, blast expansion versus dysplastic maturation, and quantitative versus qualitative platelet problems. For each pair, record the decisive evidence and what remains unresolved.
3. Make calculations transparent
Work original numerical examples for chamber counts, absolute leukocytes and reticulocytes, nucleated erythrocyte correction, RBC indices, dilutions, and CV. Write the formula, denominator, units, and any correction already applied before calculating.
4. Practise morphology and method integration
Review blood, marrow, and body fluid images alongside indices and instrument patterns. Explain what a shape, scattergram, stain, flow panel, protein study, or genetic assay establishes. In fluids, distinguish leukocytes from mesothelial cells and macrophages. Extend image study beyond the selected examples in this guide.
5. Resolve hemostasis cases in stages
Start with specimen suitability and anticoagulant exposure, then screening patterns, mixing behavior, and targeted assays. Compare bleeding-associated intrinsic deficiencies with asymptomatic contact-factor deficiencies. Practise VWF, platelet function, DIC, TTP, inherited-thrombophilia, and normal-screen bleeding cases without assigning diagnoses from a single abnormal result.
6. Review errors by reasoning category
Complete the original questions, then classify errors as mechanism, calculation, morphology, assay limitation, or laboratory operations. Revisit the relevant lessons and use flashcards for active recall. Continue into uncovered outline topics rather than treating this selective guide as the entire syllabus.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Technologist in Hematology / Specialist in Hematology Examination Content Guideline
- ASCP H/SH Suggested Reading for Examination Preparation
- NIDDK: Anemia in Chronic Kidney Disease
- American Society of Hematology: Blood Basics
- ASH Image Bank: Platelet Forming Megakaryocyte
- ARUP Consult: Iron Deficiency Anemia
- ARUP: Iron Deficiency Anemia and Anemia of Chronic Disease/Inflammation Testing Algorithm
- ARUP Consult: Megaloblastic Anemia
- ARUP Consult: Chronic Myeloid Leukemia
- ISTH Guidelines for the Diagnosis of Thrombotic Thrombocytopenic Purpura
- ARUP Consult: Thrombotic Microangiopathies
- CDC NHANES 2011–2012: Complete Blood Count Using HMX
- Sysmex: WBC Abnormal Scattergram with NRBC
- ARUP Consult: Hemolytic Anemias
- ARUP Consult: Paroxysmal Nocturnal Hemoglobinuria
- ARUP Consult: Hemophilia—Factor VIII or IX Deficiency
- ASH ISTH NHF WFH 2021 Guidelines on the Diagnosis of von Willebrand Disease
- ARUP Consult: Von Willebrand Disease
- ARUP Consult: Disseminated Intravascular Coagulation
- ARUP: Lupus Anticoagulant Reflex Panel
- ARUP Consult: Prolonged Clotting Time Evaluation
- WHO Laboratory Quality Management System: Quality Control Chapters
- OSHA: Bloodborne Pathogens Standard, 29 CFR 1910.1030
- ARUP Consult: Thalassemias
- ARUP: Glucose-6-Phosphate Dehydrogenase Test Fact Sheet
- ARUP Consult: Hemoglobinopathies
- ASH Image Bank: Iron Deficiency Anemia—Stains
- ARUP Consult: Functional Platelet Disorders
- ARUP Consult: Uncommon Factor Deficiencies
- CMS: Proficiency Testing Program Requirements—General and Cytology
- SEER Hematopoietic and Lymphoid Neoplasm Database
- pdf-1863.pdf
- Impact%20of%20Anticoagulants%20on%20Coagulation%20Testing_web.pdf
- Hemostasis-Thrombosis.pdf
- clia-brochure-proficiency-testing-and-pt-referral-october-2024.pdf
- Story of Discovery: Erythroferrone–new regulator of iron balance - NIDDK
- iwcll-guideline-hallek-et-al-2018.pdf
- Acute Myeloid Leukemia Treatment (PDQ®) - NCI
- Reactive mesothelial cells in pericardial effusion 1
- Macrophage in BALF
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®) - NCI
- IMWG Criteria for the Diagnosis of MM | Inl Myeloma Fn
- ash-teaching-slide-setvwddiagnosis-and-managementpdffinal71923.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.